Search

Background: With the introduction of direct‐acting antiviral therapies (DAAs), the non‐use rate of hepatitis C virus (HCV)‐positive donor organs (D+) has decreased significantly. We present the donor, recipient, and transplant allograft characteristics, along with recipient outcomes, in one of the largest cohorts of HCV‐D+ transplants into HCV‐naïve recipients (R−). Methods: Charts of HCV D+/R− kidney (KT), liver (LT), and simultaneous liver‐kidney (SLKT) transplant recipients between January 2019 and July 2022 were reviewed. Primary outcomes of interest included waitlist times and 1‐year graft failure. Secondary outcomes included hospital and intensive care unit length of stay, post‐transplant complications, effectiveness of DAA therapy, and characteristics of patients who relapsed from initial DAA therapy. Results: Fifty‐five HCV D+/R− transplants at our center [42 KT (26 nucleic acid testing positive [NAT+], 16 NAT−), 12 LT (eight NAT+, four NAT−), and one SLKT (NAT+)] had a median waitlist time of 69 days for KT, 87 days for LT, and 15 days for SLKT. There were no graft failures at 1 year. All viremic recipients were treated with a 12‐week course of DAAs, of which 100% achieved end of treatment response (EOTR)—85.7% (n = 30) achieved sustained virologic response (SVR) and 14.3% relapsed (n = 5; four KT, one LT). All relapsed recipients were retreated and achieved SVR. The most common post‐transplantation complications include BK virus infection (n = 9) for KT and non‐allograft infections (n = 4) for LT. Conclusions: Our study has demonstrated no graft failures or recipient deaths at 1 year, and despite a 14.3% relapse rate, we achieved 100% SVR. Complications rates of D+/R− appeared comparable to national D−/R− complication rates. Further studies comparing D+/R− to D−/R− outcomes are needed. [ABSTRACT FROM AUTHOR]

The article presents a case study of a 68-year-old female with a history of deceased donor kidney transplant with abdominal pain and lethargy. Topics include the patient having diabetes and receiving several mg/kg of thymoglobulin only at the time of induction and her immunosuppressive regimen consisting of tacrolimus, mycophenolic acid and prednisone.

Background: The coronavirus disease 2019 (COVID‐19) pandemic has created unprecedented challenges for solid organ transplant programs worldwide. The aim of this study is to assess an international perspective on challenges faced by kidney transplant programs. Methods: We administered an electronic survey instrument from January 3, 2021 to June 8, 2021 to staff at transplant programs outside the United States that comprised of 10 questions addressing the management of kidney transplant candidates with asymptomatic COVID‐19 infection or unvaccinated who receive an organ offer. Results: Respondents (n = 62) represented 19 countries in five continents. Overall, 90.3% of respondents encourage vaccination on the waiting list and prior to planned living donor transplant. Twelve percent of respondents reported that they have decided to inactivate unsensitized candidates (calculated panel reactive antibody, cPRA <80%) until they received the two doses of vaccination, and 7% report inactivating candidates who have received their first vaccine dose pending receipt of their second dose. The majority (88.5%) of international respondents declined organs for asymptomatic, nucleic acid testing (NAT)+ patients during admission without documented prior infection. However, 22.9% of international respondents proceeded with kidney transplant in NAT+ patients who were at least 30 days from initial diagnosis with negative chest imaging. Conclusions: Practitioners in some countries are less willing to accept deceased donor organs for waitlist candidates with incomplete COVID‐19 vaccination status and to wait longer before scheduling living donor transplant, compared to United States practices. Access to vaccinations and other resources may contribute to these differences. More research is needed to guide the optimal approach to vaccination before and after transplant. [ABSTRACT FROM AUTHOR]

Azole resistance in Aspergillus fumigatus is increasing worldwide and can affect prognosis. It is mostly mediated by cytochrome P51 (CYP51) mutations. In lung transplant recipients (LTR), little is known regarding the prevalence and clinical impact of CYP51 mutations. One hundred thirty-one consecutive A. fumigatus isolates from 103 patients were subjected to CYP51A genotyping through PCR and sequencing. Antifungal susceptibility testing was performed using the Sensititre YeastOne YO-9© broth microdilution technique. Correlations between genotype, phenotype, clinical manifestations of Aspergillus infection, and clinical outcomes were made. Thirty-four (26%) isolates harbored mutations of CYP51A; N248K (n = 14) and A9T (n = 12) were the most frequent. Three isolates displayed multiple point mutations. No significant influences of mutational status were identified regarding azole MICs, the clinical presentation of Aspergillus disease, 1-year all-cause mortality, and clinical outcomes of invasive forms. In the specific context of lung transplant recipients, non-hotspot CYP51A-mutated isolates are regularly encountered; this does not result in major clinical consequences or therapeutic challenges. Lay Summary In 131 isolates of Aspergillus fumigatus isolates originating from 103 lung transplant recipients, the CYP51A polymorphism rate was 26%, mostly represented by N248K and A9T mutations. These mutations, however, did not significantly impact azoles minimal inhibitory concentrations or clinical outcomes. [ABSTRACT FROM AUTHOR]

Elizabethkingia anophelis is an emerging pathogen increasingly implicated in health care-associated infections. Here, we report a case of recurrent ventricular assist device-associated infection caused by multidrug-resistant Elizabethkingia anophelis and describe the clinical course, treatment challenges, and ultimate case resolution. Our results demonstrate that standard clinical methodologies for determining trimethoprim-sulfamethoxazole minimum inhibitory concentration, including VITEK2 and gradient diffusion tests, may be unsuitable for Elizabethkingia anophelis as they result in false-negative susceptibility results. The discrepancy between antimicrobial susceptibility testing reported here highlights the importance of investigating and validating the applicability of standard clinical antimicrobial susceptibility testing and interpretation when treating emerging pathogens such as Elizabethkingia anophelis., Competing Interests: Potential conflicts of interest. All authors: no reported conflicts., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Competing Interests: Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.